AI Article Synopsis
Article Abstract
Introduction: Factors that influence antidepressant (AD) prescription and use during pregnancy are multiple including, in particular, the balance between the potential risk of untreated depression and the potential risk of AD treatment. Surveillance of temporal trends of AD use might identify areas requiring further research. We studied the use of ADs before, during, and after pregnancy using national data across two decades in Denmark.
Methods: We included 1,232,233 pregnancies leading to live birth in Denmark between 1 January 1997 and 31 December 2016. Information on redemption of AD prescriptions was obtained from the Danish National Prescription Register.
Results: We identified 29,504 (2.4%) pregnancies having at least one AD prescription (96,232 AD prescriptions) during pregnancy. The majority redeemed more than one prescription (69.7%) often for a single kind of AD (83.5%), and in 94% of the AD-exposed pregnancies, the estimated duration of treatment was 1 month or longer. Prescription of ADs during pregnancy increased steadily from 0.4% in 1997 to 4.6% in 2011, but decreased thereafter to 3.1% in 2016. The proportion of pregnancies with ADs in 2011 was 6.05-fold higher than that in 1997. The temporal trends in AD prescription in the years before and after pregnancy were similar to the trend during pregnancy. The decreasing use of ADs during pregnancy after 2011 was mainly driven by a decrease in the use of selective serotonin reuptake inhibitors (SSRIs), especially citalopram, the main type of SSRIs used in Denmark.
Conclusion: Prescription of ADs during pregnancy in Denmark increased steadily from 1997 to 2011 but decreased sharply thereafter. More research is needed to show whether the same trend exists in other populations, like women of reproductive age, men of reproductive age, and old people, and other countries. We also need to find explanation for the decreasing trend in recent years and potential risk for untreated depression.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851806 | PMC |
| http://dx.doi.org/10.1002/brb3.1441 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pregnancy mobile app use: A survey of health information practices and quality awareness among pregnant women in Australia.
Womens Health (Lond)
November 2024
Monash Centre for Health Research and Implementation, School of Public Health and Preventive Medicine, Monash University, Clayton, VIC, Australia.
Background: Health-related mobile applications (apps) have the potential to improve health knowledge and promote healthy behaviours during pregnancy. Pregnancy apps are popular and extensively used by consumers.
Objective: This study investigates the usage patterns, decision-making criteria and concerns regarding the quality and credibility of health-related information within pregnancy mobile applications.
Neighborhood demographics in relation to marketing and regulation-related factors among cannabis retailers in 5 US cities.
Drug Alcohol Depend
December 2024
Stanford Prevention Research Center, Stanford University School of Medicine, Palo Alto, CA, USA.
Objectives: This study assessed differences in cannabis retailer practices by neighborhood sociodemographics, which can inform disparity-relevant interventions.
Methods: Multilevel multivariable logistic regressions examined retailers' census tract demographics (percent <21 years-old; non-Hispanic White, Black, or other race, Hispanic; median household income [MHHI]) in relation to 2022 audit data regarding marketing (youth-oriented signs, health-claims, exterior ads, price specials, membership programs, delivery/pick-up) and regulatory compliance (pregnancy and health-risk warning signage, exterior minimum-age signage) among 150 randomly-selected retailers in 5 US cities/states (Denver, Colorado; Seattle, Washington; Portland, Oregon; Las Vegas, Nevada; Los Angeles, California).
Results: 20.
A Phase 1b PK/PD Study to Demonstrate Antigen Elimination with RLYB212, a Monoclonal Anti-HPA-1a Antibody for FNAIT Prevention.
Thromb Haemost
September 2024
Division Clinical Research, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany.
Article Synopsis
- Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a rare condition where a mother’s immune system attacks her fetus's platelets, primarily due to antibodies against the HPA-1a antigen; current prevention and treatment options are lacking.
- A study tested the efficacy of RLYB212, a monoclonal antibody that targets HPA-1a, to see if it could eliminate HPA-1a-positive platelets after a simulated fetal-maternal hemorrhage; subjects received either RLYB212 or a placebo in a blind trial.
- Results showed that RLYB212 significantly reduced HPA-1a-positive platelets and was well tolerated, indicating its promise as a potential
Perinatal intimate partner violence among teen mothers and children's attachment disorders in Rwanda: potential mediating factors.
Eur J Psychotraumatol
August 2024
Department of Clinical Psychology, College of Medicine and Health sciences, University of Rwanda, Kigali, Rwanda.
The alarming prevalence of teen mothers' exposure to perinatal intimate partner violence (IPV, 8.3-67%) and attachment disorders (ADs) among their children is a global concern, especially in sub-Saharan Africa with high teenage pregnancy rates. This study, therefore, aimed to examine the link between teen IPV and AD in their offspring.
View Article and Find Full Text PDFAntidepressants and fetal death: A systematic review and disproportionality analysis in the WHO safety database (VigiBase).
Psychiatry Res
September 2024
Centre Hospitalier Universitaire de Caen Normandie, service de psychiatrie de l'enfant et de l'adolescent, Avenue de la côte de nacre, 14000, Caen, France. Electronic address:
Recent research suggests that fetal exposure to antidepressants (ADs) is significantly associated with fetal death, including stillbirth. However, there has been limited investigation into the timing of AD exposure during pregnancy, the specific effect of each drug, and the possibility of indication bias. To address these gaps in knowledge, we conducted a systematic review of literature and disproportionality analyses using the WHO Safety Database (VigiBase).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!